GlassScriptPhysician profile
Joan Marie Schieber
NPI 1760437354
$3,317.11
in general payments reported to CMS, 2019-2025
31 companies · $673 in 2025
The $673 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $347 · 2021: $613 · 2022: $289 · 2023: $271 · 2024: $792 · 2025: $673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,691 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.25 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $649.45 | 2019-2025 | Lo Loestrin Fe |
| Pfizer INC. | $406.78 | 2019-2025 | |
| Astellas Pharma US INC | $240.74 | 2023-2025 | Veozah, Myrbetriq |
| Shield Therapeutics INC | $229.50 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $209.47 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $205.14 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.90 | 2019-2024 | |
| Millicent US INC | $111.58 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Daiichi Sankyo INC. | $109.42 | 2019-2023 | Injectafer |
| Evofem Biosciences, INC. | $103.27 | 2021-2022 | |
| Organon LLC | $92.16 | 2023-2025 | Nexplanon, Jada System |
| Medtronic, INC. | $81.94 | 2024-2025 | Endo Stitch, Ligasure, Rapidvac |
| Biogen, INC. | $74.56 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $66.50 | 2019-2022 | |
| Myovant Sciences INC. | $64.14 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $63.39 | 2024-2025 | Wegovy |
| Amgen INC. | $58.23 | 2021-2023 | Evenity, Prolia |
| Allergan, INC. | $55.82 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $54.06 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $51.90 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.08 | 2019-2025 | Gardasil 9 |
| Pacira Pharmaceuticals Incorporated | $36.99 | 2023 | Exparel |
| Scynexis, INC. | $27.49 | 2022 | |
| Agile Therapeutics, INC. | $26.64 | 2022 | |
| Avion Pharmaceuticals | $22.55 | 2020-2021 | |
| Lilly USA, LLC | $19.74 | 2025 | Zepbound |
| Hologic Sales and Service, LLC | $18.52 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.67 | 2019 | |
| Bausch Health US, LLC | $16.09 | 2020 | |
| Exeltis, USA INC. | $14.63 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Schieber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.